FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952026754> ?p ?o ?g. }

• W2952026754 abstract "5062 Background: The receptor for luteinizing hormone releasing hormone (LHRH-R) is highly expressed on CRPC cells and is a potential therapeutic target. AEZS-108 is an LHRH-cytotoxic hybrid that covalently couples an LHRH agonist with doxorubicin. We report the completed Phase I trial of AEZS-108 in men with taxane-resistant CRPC. We explored visualization of AEZS-108 internalization into circulating tumor cells (CTCs) exploiting the auto-fluorescence of doxorubicin and also tested LHRH-R expression on CTCs. Methods: This was a dose escalation Phase I trial in men with taxane-resistant CRPC to confirm the dose established in a phase I trial in women. Standard 3+3 design was used with planned expansion at the MTD to ensure 6 patients received 2+ courses without DLT. Eligibility criteria included progression of disease despite prior LHRH agonist and taxane therapy. Patients received AEZS-108 every 21 days until progression or unacceptable toxicity. The primary endpoint was safety. CTCs were captured with a novel slot microfilter and identified by PSA and DAPI staining. AEZS-108 internalization was visualized by fluorescence microscopy. Results: Eighteen men with a median of 2 prior chemotherapy regimens (range 1-5) and a median PSA of 106.4 ng/mL (range 8.4-1624.0) enrolled from November 2010 to August 2012. The dose was escalated from 160 mg/m 2 to 210 mg/m 2 then to 267 mg/m 2 . There were 2 DLTs in the 7 men receiving 267 mg/m 2 (grade 4 neutropenia), prompting de-escalation to 210 mg/m 2 where 1 of 8 men experienced a DLT (grade 4 neutropenic fever), establishing 210 mg/m 2 as the MTD. Significant non-hematologic toxicities included a case of grade 3 nausea. No cardiotoxicity was seen on serial evaluation and 6 patients completed 6 cycles. Internalization of AEZS-108 was consistently visualized in CTCs 1-3 hours after dosing. Maximal PSA response was stable or decreased in 8 of 18 men. Conclusions: The MTD of AEZS-108 in men with taxane-resistant CRPC is 210 mg/m 2 , which is below the MTD reported in women with refractory endometrial, ovarian and breast cancer. The activity of AEZS-108 was promising in this heavily pretreated population. The Phase II portion is currently accruing. Clinical trial information: NCT01240629." @default.
• W2952026754 created "2019-06-27" @default.
• W2952026754 creator A5009732369 @default.
• W2952026754 creator A5020334875 @default.
• W2952026754 creator A5031088617 @default.
• W2952026754 creator A5043871151 @default.
• W2952026754 creator A5047212274 @default.
• W2952026754 creator A5053173451 @default.
• W2952026754 creator A5062167990 @default.
• W2952026754 creator A5067387322 @default.
• W2952026754 creator A5068739269 @default.
• W2952026754 creator A5091696839 @default.
• W2952026754 date "2013-05-20" @default.
• W2952026754 modified "2023-10-17" @default.
• W2952026754 title "A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)." @default.
• W2952026754 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.5062" @default.
• W2952026754 hasPublicationYear "2013" @default.
• W2952026754 type Work @default.
• W2952026754 sameAs 2952026754 @default.
• W2952026754 citedByCount "1" @default.
• W2952026754 countsByYear W29520267542014 @default.
• W2952026754 crossrefType "journal-article" @default.
• W2952026754 hasAuthorship W2952026754A5009732369 @default.
• W2952026754 hasAuthorship W2952026754A5020334875 @default.
• W2952026754 hasAuthorship W2952026754A5031088617 @default.
• W2952026754 hasAuthorship W2952026754A5043871151 @default.
• W2952026754 hasAuthorship W2952026754A5047212274 @default.
• W2952026754 hasAuthorship W2952026754A5053173451 @default.
• W2952026754 hasAuthorship W2952026754A5062167990 @default.
• W2952026754 hasAuthorship W2952026754A5067387322 @default.
• W2952026754 hasAuthorship W2952026754A5068739269 @default.
• W2952026754 hasAuthorship W2952026754A5091696839 @default.
• W2952026754 hasConcept C121608353 @default.
• W2952026754 hasConcept C126322002 @default.
• W2952026754 hasConcept C143998085 @default.
• W2952026754 hasConcept C2776056953 @default.
• W2952026754 hasConcept C2776235491 @default.
• W2952026754 hasConcept C2777511904 @default.
• W2952026754 hasConcept C2777899217 @default.
• W2952026754 hasConcept C2778971682 @default.
• W2952026754 hasConcept C2780192828 @default.
• W2952026754 hasConcept C530470458 @default.
• W2952026754 hasConcept C71924100 @default.
• W2952026754 hasConceptScore W2952026754C121608353 @default.
• W2952026754 hasConceptScore W2952026754C126322002 @default.
• W2952026754 hasConceptScore W2952026754C143998085 @default.
• W2952026754 hasConceptScore W2952026754C2776056953 @default.
• W2952026754 hasConceptScore W2952026754C2776235491 @default.
• W2952026754 hasConceptScore W2952026754C2777511904 @default.
• W2952026754 hasConceptScore W2952026754C2777899217 @default.
• W2952026754 hasConceptScore W2952026754C2778971682 @default.
• W2952026754 hasConceptScore W2952026754C2780192828 @default.
• W2952026754 hasConceptScore W2952026754C530470458 @default.
• W2952026754 hasConceptScore W2952026754C71924100 @default.
• W2952026754 hasLocation W29520267541 @default.
• W2952026754 hasOpenAccess W2952026754 @default.
• W2952026754 hasPrimaryLocation W29520267541 @default.
• W2952026754 hasRelatedWork W1902440608 @default.
• W2952026754 hasRelatedWork W2089874898 @default.
• W2952026754 hasRelatedWork W2261036306 @default.
• W2952026754 hasRelatedWork W2280175857 @default.
• W2952026754 hasRelatedWork W2324517748 @default.
• W2952026754 hasRelatedWork W2340106430 @default.
• W2952026754 hasRelatedWork W2472772837 @default.
• W2952026754 hasRelatedWork W2511127942 @default.
• W2952026754 hasRelatedWork W2601530548 @default.
• W2952026754 hasRelatedWork W2602525805 @default.
• W2952026754 hasRelatedWork W2752890348 @default.
• W2952026754 hasRelatedWork W2797645683 @default.
• W2952026754 hasRelatedWork W2892144772 @default.
• W2952026754 hasRelatedWork W2907681731 @default.
• W2952026754 hasRelatedWork W2921220739 @default.
• W2952026754 hasRelatedWork W2947474220 @default.
• W2952026754 hasRelatedWork W2967232370 @default.
• W2952026754 hasRelatedWork W3008027775 @default.
• W2952026754 hasRelatedWork W3032541144 @default.
• W2952026754 hasRelatedWork W3178279368 @default.
• W2952026754 isParatext "false" @default.
• W2952026754 isRetracted "false" @default.
• W2952026754 magId "2952026754" @default.
• W2952026754 workType "article" @default.